Plain-English translation of NCT06095765 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Coronary Artery Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called colchicine, taken as a daily pill, can help prevent future heart problems in people who have recently had a stent placed to open a blocked coronary artery. Half of the participants will receive the medication, and half will receive a placebo (a pill with no active ingredient), while continuing their regular heart medications and care. The study will follow participants for several years to see if the medication reduces the risk of future heart events.
Even after a stent is placed and patients receive standard heart medications, many people still experience future heart problems. This medication might work by reducing inflammation in the arteries, and researchers want to find out if it can provide extra protection beyond current treatments.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either the medication or a placebo pill once daily, along with your regular heart medications. You will visit the clinic one month after starting the study, then once yearly for standard heart care visits, with phone check-ins every 6 months in between. During visits, you'll answer questions about your health and any heart-related events. The study continues until enough participants have experienced a heart event to determine whether the medication works—this may take several years.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
Belgium